» Articles » PMID: 38408048

Detection of Driver Mutations and Genomic Signatures in Endometrial Cancers Using Artificial Intelligence Algorithms

Overview
Journal PLoS One
Date 2024 Feb 26
PMID 38408048
Authors
Affiliations
Soon will be listed here.
Abstract

Analyzed endometrial cancer (EC) genomes have allowed for the identification of molecular signatures, which enable the classification, and sometimes prognostication, of these cancers. Artificial intelligence algorithms have facilitated the partitioning of mutations into driver and passenger based on a variety of parameters, including gene function and frequency of mutation. Here, we undertook an evaluation of EC cancer genomes deposited on the Catalogue of Somatic Mutations in Cancers (COSMIC), with the goal to classify all mutations as either driver or passenger. Our analysis showed that approximately 2.5% of all mutations are driver and cause cellular transformation and immortalization. We also characterized nucleotide level mutation signatures, gross chromosomal re-arrangements, and gene expression profiles. We observed that endometrial cancers show distinct nucleotide substitution and chromosomal re-arrangement signatures compared to other cancers. We also identified high expression levels of the CLDN18 claudin gene, which is involved in growth, survival, metastasis and proliferation. We then used in silico protein structure analysis to examine the effect of certain previously uncharacterized driver mutations on protein structure. We found that certain mutations in CTNNB1 and TP53 increase protein stability, which may contribute to cellular transformation. While our analysis retrieved previously classified mutations and genomic alterations, which is to be expected, this study also identified new signatures. Additionally, we show that artificial intelligence algorithms can be effectively leveraged to accurately predict key drivers of cancer. This analysis will expand our understanding of ECs and improve the molecular toolbox for classification, diagnosis, or potential treatment of these cancers.

Citing Articles

From Genes to Clinical Practice: Exploring the Genomic Underpinnings of Endometrial Cancer.

Molefi T, Mabonga L, Hull R, Sebitloane M, Dlamini Z Cancers (Basel). 2025; 17(2).

PMID: 39858102 PMC: 11763595. DOI: 10.3390/cancers17020320.


CD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.

Hirsch R, Premsankar S, Kurnit K, Chiou L, Rabjohns E, Lee H bioRxiv. 2024; .

PMID: 39605508 PMC: 11601622. DOI: 10.1101/2024.11.18.624183.


In silico analysis of several frequent SLX4 mutations appearing in human cancers.

Bosart K, Petreaca R, Bouley R MicroPubl Biol. 2024; 2024.

PMID: 38828439 PMC: 11143449. DOI: 10.17912/micropub.biology.001216.

References
1.
Dixit A, Verkhivker G . Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Comput Math Methods Med. 2014; 2014:653487. PMC: 4000980. DOI: 10.1155/2014/653487. View

2.
Chi A, Batchelor T, Dias-Santagata D, Borger D, Stiles C, Wang D . Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol. 2012; 110(1):89-98. PMC: 3583376. DOI: 10.1007/s11060-012-0938-9. View

3.
Morin P, Sparks A, Korinek V, Barker N, Clevers H, Vogelstein B . Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275(5307):1787-90. DOI: 10.1126/science.275.5307.1787. View

4.
Provost E, McCabe A, Stern J, Lizardi I, DAquila T, Rimm D . Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene. 2005; 24(16):2667-76. DOI: 10.1038/sj.onc.1208346. View

5.
Temko D, Van Gool I, Rayner E, Glaire M, Makino S, Brown M . Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018; 245(3):283-296. PMC: 6032922. DOI: 10.1002/path.5081. View